Abstract
Clinical studies provide overwhelming evidence for the importance of proteolytic imbalance and the upregulation of diverse protease classes in diseases such as cancer and arthritis. While the complex nature of proteolytic networks has hampered the development of protease inhibitors for these indications, aberrant enzyme activity could be successfully exploited for the development of proteasesensitive drug delivery systems and fluorescent in vivo imaging agents. More recently, these concepts have also been translated into photomedical applications to develop dual modality prodrugs for the simultaneous treatment and imaging of disease. After an introductory overview of proteases and their role in cancer, we present and discuss different strategies to exploit upregulated protease activity for the development of drug delivery systems, fluorescent in vivo reporter probes, and photosensitizer-prodrugs with respect to their potential and limitations. The main approaches used for targeting proteases in all three areas can be roughly divided into peptide-based and macromolecular strategies. Both involve the use of a short, peptide-based protease substrate, which is either directly tagged to the therapeutic agent or dye/quencher pair, or alternatively, serves as a linker between the polymeric carrier and a functional unit. In the latter case, the pharmacokinetic properties of peptide-based protease-sensitive prodrugs and imaging probes can be further ameliorated by the passive targeting capacity of macromolecular drug delivery systems for neoplastic and inflammatory lesions.
Keywords: Peptide-based prodrugs, polymeric prodrugs, proteases, protease-sensitive fluorescence imaging agents, protease-sensitive chemotherapeutics, protease-sensitive photosensitizers, drug delivery, photodynamic therapy, hydrolysis of peptide, overwhelming evidence
Current Medicinal Chemistry
Title: It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Volume: 18 Issue: 12
Author(s): D. Gabriel, M. F. Zuluaga, H. van den Bergh, R. Gurny and N. Lange
Affiliation:
Keywords: Peptide-based prodrugs, polymeric prodrugs, proteases, protease-sensitive fluorescence imaging agents, protease-sensitive chemotherapeutics, protease-sensitive photosensitizers, drug delivery, photodynamic therapy, hydrolysis of peptide, overwhelming evidence
Abstract: Clinical studies provide overwhelming evidence for the importance of proteolytic imbalance and the upregulation of diverse protease classes in diseases such as cancer and arthritis. While the complex nature of proteolytic networks has hampered the development of protease inhibitors for these indications, aberrant enzyme activity could be successfully exploited for the development of proteasesensitive drug delivery systems and fluorescent in vivo imaging agents. More recently, these concepts have also been translated into photomedical applications to develop dual modality prodrugs for the simultaneous treatment and imaging of disease. After an introductory overview of proteases and their role in cancer, we present and discuss different strategies to exploit upregulated protease activity for the development of drug delivery systems, fluorescent in vivo reporter probes, and photosensitizer-prodrugs with respect to their potential and limitations. The main approaches used for targeting proteases in all three areas can be roughly divided into peptide-based and macromolecular strategies. Both involve the use of a short, peptide-based protease substrate, which is either directly tagged to the therapeutic agent or dye/quencher pair, or alternatively, serves as a linker between the polymeric carrier and a functional unit. In the latter case, the pharmacokinetic properties of peptide-based protease-sensitive prodrugs and imaging probes can be further ameliorated by the passive targeting capacity of macromolecular drug delivery systems for neoplastic and inflammatory lesions.
Export Options
About this article
Cite this article as:
Gabriel D., F. Zuluaga M., van den Bergh H., Gurny R. and Lange N., It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine, Current Medicinal Chemistry 2011; 18 (12) . https://dx.doi.org/10.2174/092986711795496782
DOI https://dx.doi.org/10.2174/092986711795496782 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Human Methylome Variation and the Rise of Epigenetic Epidemiology]
Current Pharmacogenomics and Personalized Medicine Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets Treatment of Chronic Pain with Drugs that Modulate Central Nervous System Serotonin and Norepinephrine
Current Drug Therapy Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs
Current Medicinal Chemistry Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Regulation of Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Soluble Epoxide Hydrolase Inhibitors and their Potential for Treatment of Multiple Pathologic Conditions
Current Medicinal Chemistry The Wnt/Beta-Catenin Pathway in Wilms Tumors and Prostate Cancers
Current Molecular Medicine The Function of the Selective Inhibitors of Cycloxygenase 2
Mini-Reviews in Medicinal Chemistry Genomic Sequence Analysis of EGFR Regulation by MicroRNAs in Lung Cancer
Current Topics in Medicinal Chemistry Molecular Mechanisms and Proposed Targets for Selected Anticancer Gold Compounds
Current Topics in Medicinal Chemistry New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Protein Transduction Domains: Applications for Molecular Medicine
Current Gene Therapy Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation
Current Pharmacogenomics and Personalized Medicine Organosulfur Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Ovarian Granulosa Cell Tumor: A Clinicoradiologic Series with Literature Review
Current Medical Imaging Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy